CJC-1295 (no DAC)

Modified GRF 1-29 / GHRH Analogue

CJC-1295 (no DAC) hits the GHRH pathway, which is a different receptor than ipamorelin. That's the whole reason you stack them. CJC tells your pituitary 'make more GH' while ipamorelin tells it 'release what you've made.' The no-DAC version is short-acting on purpose — it gives you a natural pulse instead of a sustained flood. Your body's GH release is pulsatile, and you want to work with that pattern, not blast through it.

Protocol

Dose: 100-200mcg per day | Frequency: Once nightly with ipamorelin, on an empty stomach | Cycle: 8-12 weeks on, 4 weeks off | Route: SubQ

Reconstitution: 2mL bacteriostatic water per 5mg vial. Use our free reconstitution calculator for exact syringe units.

Effects

• Enhanced GH pulse (75%) — Amplifies the growth hormone release when combined with ipamorelin
• Improved recovery (62%) — Faster recovery from training and injury, particularly noticeable after 2-3 weeks
• Fat loss (50%) — Gradual improvement in body composition, especially stubborn midsection fat
• Better sleep (48%) — Deeper, more restorative sleep from the nightly GH pulse

Side Effects

• Flushing / warmth (22%) — Your face and chest get warm and flushy about 5-10 minutes after pinning. Totally harmless but it'll freak you out the first time.
• Water retention (18%) — You might feel a bit puffy the first couple weeks. Settles down on its own.
• Headache (10%) — Mild headache sometimes, more likely if you're dosing on the higher end.
• Tingling / numbness (8%) — Carpal tunnel-ish tingling in your hands means your GH is running too high. Drop the dose.

Evidence

Emerging evidence — CJC-1295 without DAC (also called Mod GRF 1-29) is a short-acting GHRH analog that produces a brief, pulsatile GH release. The DAC version has more human data but causes sustained GH elevation, which is less physiological. The no-DAC version is preferred in community protocols for mimicking natural GH patterns.

Approval status: Not approved

References

1. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults J Clin Endocrinol Metab, 2006. PMID: 16352683
2. Ionescu M et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog J Clin Endocrinol Metab, 2006. PMID: 17018654
3. Alba M et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse Am J Physiol Endocrinol Metab, 2006. PMID: 16822960
4. Sackmann-Sala L et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects Growth Horm IGF Res, 2009. PMID: 19386527
5. Van Hout MC et al. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions Subst Use Misuse, 2016. PMID: 26771670
6. Memdouh S et al. Advances in the detection of growth hormone releasing hormone synthetic analogs Drug Test Anal, 2021. PMID: 34665524

Storage

• Lyophilized: Refrigerate at 2-8C. Keep away from light. Stable for 12+ months sealed.
• Reconstituted: Refrigerate. Use within 3-4 weeks. CJC is slightly more fragile than ipamorelin.
• Water: Bacteriostatic water, 2mL per 5mg vial.
• Needle: 29-31 gauge, 0.5 inch for subcutaneous injection

← Browse all peptides | Dose calculator →

These statements have not been evaluated by the FDA. This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any protocol.

vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify